Drug Profile
Research programme: antibacterials - Microbia
Alternative Names: Anti-Biofilm therapeutics; Antibacterials research programme - MicrobiaLatest Information Update: 31 Jul 2006
Price :
$50
*
At a glance
- Originator Harvard Medical School
- Developer Dartmouth Medical School; Whitehead Institute for Biomedical Research
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 31 Jul 2006 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
- 12 Jun 2003 This programme is still in active development
- 04 Dec 2000 This programme is available for licensing (http://www.microbia.com)